GC Biopharma Presents IVIG Data at CIS 2026

GC Biopharma USA has presented new data on intravenous immunoglobulin product characteristics at the 2026 Clinical Immunology Society Annual Meeting in New Orleans. The presentations included two company-authored posters covering molecular size distribution under mechanical stress and viscosity across IVIG preparations, alongside a third externally led study on contaminant protein signatures. The data adds to growing analytical work aimed at differentiating IVIG products as global demand continues to expand.

The first company-authored poster, presented by Stacey Ness, PharmD, examined the impact of mechanical stress on molecular size distribution in ALYGLO, GC Biopharma’s 10% liquid IVIG product. The second, presented by Suzanne Strasters, MSN, investigated viscosity across commercially available immunoglobulin preparations. Both studies sit within Medical Affairs’ broader programme of analytical characterisation work.

A third poster, supported through GC Biopharma’s Investigator-Initiated Research Program and led by Benjamin Gabriel, Ph.D. of EpiVax, used the ISPRI-HCP platform to evaluate product-specific human contaminant protein signatures across four commercial IVIG products. The authors concluded that in silico screening of contaminant signatures may help identify product-specific immunogenicity drivers and inform future IVIG optimisation.

GC Biopharma also hosted a lunch symposium titled “From Molecules to Tolerability: Understanding Immunoglobulins and Immunogenicity Through Advanced Molecular Characterization”, presented by Kevin Van Cott, Ph.D. The wider sector context is one of rising IVIG demand driven by improved recognition of primary immunodeficiencies and broader use in immune-mediated conditions, where product purity, stability and tolerability are key differentiators.

The CIS presentations reinforce GC Biopharma’s positioning around analytical depth and product characterisation as IVIG becomes an increasingly differentiated category. With manufacturers competing on purity, aggregation profile and tolerability rather than therapeutic class alone, the volume of comparative analytical research is likely to keep rising across plasma-derived players over the next 12 months and shape commercial positioning as new products enter the market.

For the latest updates and in-depth insights into the world of Analytical Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!